A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 731 participants.
Also called NCT06610526
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 731 participants
- Sponsor
- Registry
-
NCT06610526
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06610526. Non-randomized; no masking; primary purpose treatment. Start 2024-08-23 (actual); primary completion 2027-05-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Dapagliflozin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct06610526- Content hash
c2c46ba18c8f3f344cc27fca396d9976cbde756b0defd12691bf651e02c8226a